Evidence map›Paper›PMID 37289003›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

The Impact of Germline Alterations in Appendiceal Adenocarcinoma.

Michael B Foote, Henry Walch, Yelena Kemel, Efsevia Vakiani, Paul Johannet, Margaret Sheehan, Walid Chatila, Sebastian Chung, Garrett M Nash, Anna Maio and 7 more

Open access · greenAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Michael B FooteDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3027-2405
Henry WalchHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1188-350X
Yelena KemelNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5042-5651
Efsevia VakianiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0227-3523
Paul JohannetDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9264-8327
Margaret SheehanNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0003-1828-9527
Walid ChatilaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5474-218X
Sebastian ChungDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5165-4360
Garrett M NashDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9833-2625
Anna MaioNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4605-9684
Jinru ShiaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4351-2511
Diana MandelkerDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4154-0567
Michael BergerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3882-5000
Nikolaus SchultzHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0131-4904
Luis A DiazDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7079-8914
Andrea Cercek *Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5054-8192
Zsofia K Stadler *Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6985-2864
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Defining the role of GNAS in gastrointestinal metastasisK08CA279922 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Foote · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA279922NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeMore than 10% of assessed patients with appendiceal adenocarcinoma have a pathogenic (P) or likely pathogenic (LP) germline variant, including genes implicated in heritable gastrointestinal cancer syndromes, such as Lynch syndrome. We defined the clinical and molecular impact of heritable alterations in appendiceal adenocarcinoma to evaluate the need for dedicated appendiceal screening and prevention strategies in patients with LP/P germline variants. EXPERIMENTAL

designWe performed an integrated germline and somatic molecular analysis for patients with confirmed appendiceal adenocarcinoma. Patients underwent paired tumor-normal sequencing for up to 90 hereditary cancer risk genes and 505 genes for somatic mutation profiling. We defined the cooccurrence of LP/P germline variants and second-hit pathogenic somatic alterations. The associations between germline variants and patient clinicopathologic features were also evaluated.

resultsTwenty-five of 237 patients (10.5%) carried pathogenic or likely pathogenic germline variants in cancer susceptibility genes. Clinicopathologic characteristics and appendiceal adenocarcinoma-specific survival were similar in patients with or without germline variants. Most (92%, N = 23/25) patients with germline variants demonstrated no second-hit somatic alterations, including loss of heterozygosity. Two patients with a germline APC I1307K low-penetrance founder variant exhibited secondary somatic pathogenic alterations in APC. However, only one patient tumor exhibited APC-mediated WNT signaling dysregulation: a plausible consequence of multiple somatic APC mutations with no germline variant contribution. Four patients had germline variants in PMS2 or MSH2 associated with Lynch syndrome, yet their cancers were microsatellite-stable.

conclusionsGermline variants are likely incidental without a contributory driver role in appendiceal adenocarcinoma. Appendiceal adenocarcinoma screening in patients with germline variants is not clearly merited.

Indexed as

AdenocarcinomaAppendiceal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisNeoplastic Syndromes, HereditaryGenetic Predisposition to DiseaseGerm-Line MutationHumans

Identifiers

PMID37289003
PMCPMC10642170
OpenAlexW4377011754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.